Clinical application of NanoString fluorescent barcode technology in the molecular subtyping of patients with diffuse large B-cell lymphoma
10.3760/cma.j.cn115356-20210316-00052
- VernacularTitle:NanoString荧光条形码技术在弥漫大B细胞淋巴瘤分子分型中的临床应用
- Author:
Cong BAI
;
Yifan GAO
;
Xiaofan YE
;
Liping GONG
;
Wei ZHAO
;
Zifen GAO
;
Min LI
- From:
Journal of Leukemia & Lymphoma
2021;30(4):216-219
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the clinical application of NanoString fluorescent barcode technology in the molecular subtyping of diffuse large B-cell lymphoma (DLBCL), and to analyze the correlation between the cell-of-origin subtype and prognosis of patients.Methods:The tumor tissue samples of 12 patients with DLBCL at the Third People's Hospital of Datong of Shanxi Province and 8 patients with DLBCL at Peking University, Health Science Center between January 2014 and December 2019 were collected. According to Hans algorithm, all patients were divided into 1 case of germinal center-derived B-cell (GCB) type and 19 cases of non-GCB type. NanoString platform was used to analyze the expression level differences of 15 genes-related to Lymph2Cx molecular subtyping of all samples at mRNA level. Hierarchical clustering was used to subgroup 20 DLBCL cases and to contrast the prognosis in different subgroups according to the subtyping.Results:NanoString fluorescent barcode technology was used to detect samples of 20 DLBCL cases and hierarchical clustering analysis was performed, and then subtyping results showed that 11 cases were GCB-like type and 9 cases were activated B cell (ABC)-like type. Based on Hans algorithm, 10 GCB-like cases were non-GCB type. According to the survival analysis, GCB-like group had a better overall survival compared with that in ABC-like group ( P=0.019). Conclusion:NanoString fluorescent barcode technology can be successfully applied to the cell-of-origin subtyping of DLBCL, and the molecular subtyping strategy can effectively predict the prognosis of patients.
